577 filings
10-Q
2024 Q1
ALT
Altimmune Inc
Quarterly report
9 May 24
4:05pm
8-K
ALT
Altimmune Inc
9 May 24
Altimmune Announces First Quarter 2024 Financial Results and Provides a Business Update
7:04am
S-8
ALT
Altimmune Inc
27 Mar 24
Registration of securities for employees
4:10pm
10-K
2023 FY
ALT
Altimmune Inc
Annual report
27 Mar 24
4:03pm
8-K
ALT
Altimmune Inc
27 Mar 24
Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results
7:04am
8-K
8biubws8hocj4ah0
30 Nov 23
Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide
4:28pm
8-K
rxwbk bcy0f
7 Nov 23
Altimmune Announces Third Quarter 2023 Financial Results and Provides a Business Update
7:06am
8-K
3pemls8si1ihx81lyr
28 Sep 23
Submission of Matters to a Vote of Security Holders
4:55pm
ARS
mu0p726wc4d6d4t44ib
16 Aug 23
Annual report to shareholders
4:14pm
8-K
c7cg16 1s009hab
10 Aug 23
Altimmune Announces Second Quarter 2023 Financial Results and Provides a Business Update
7:04am
8-K
h0affz3f 35nc93
11 May 23
Altimmune Announces First Quarter 2023 Financial Results and Provides a Business Update
7:03am
8-K
yzv00opmn 8s0pibr4dx
27 Mar 23
Altimmune Appoints Former GSK Executive Catherine Angell Sohn, Pharm.D. to its Board of Directors
4:06pm
8-K
7ddcrraf qymtnkoa
21 Mar 23
Regulation FD Disclosure
7:04am
S-3ASR
0myhd
28 Feb 23
Automatic shelf registration
4:50pm
S-8
3g5ll6bzxoif23skk
28 Feb 23
Registration of securities for employees
4:37pm
8-K
a8a utwj3llj8co6v9i
28 Feb 23
Altimmune Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update
7:04am